According to a new market research report "Parkinson's Disease Treatment Market by Drug Class (Carbidopa/Levodopa, Dopamine Receptor Agonists, MAO-Inhibitors), Distribution Channel (Hospital, Online, Retail Pharmacies), Patient Care Setting (Hospitals, Clinics) - Global Forecast to 2022", published by MarketsandMarkets™, the market is expected to reach USD 5.69 Billion by 2022 from USD 4.24 Billion in 2017, at a CAGR of 6.1%.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=47265247
The Parkinson’s disease treatment market is segmented on the basis of drug class, distribution channel, patient care setting, and region. On the basis of drug class, the market is segmented into carbidopa/levodopa, dopamine receptor agonists, MAO-inhibitors, COMT-inhibitors, anticholinergics and other drugs. The carbidopa/levodopa segment is expected to account for the largest share of the market in 2017. The growth in this segment is primarily attributed to the potency of the drug.
By distribution channel, the market is segmented into hospital pharmacies, retailer pharmacies, and online pharmacies. In 2017, the hospital pharmacies segment accounted for the largest share of the market. Increasing number of patient visits to the hospital due to the availability of diagnostic laboratories and presence of skilled neurologists are driving the growth of hospital pharmacies segment.
On the basis of patient care setting, the Parkinson’s disease treatment market is segmented into hospitals and clinics. In 2017, hospitals are expected to account for the largest share of the market. Robust health infrastructure and presence of skilled neurologists are the driving factors for hospital segment.
Request for Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=47265247
By region, the Parkinson’s disease treatment market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). The market is dominated by Europe, followed by North America, however, the Asian region is expected to witness the highest growth during the forecast period. Asia is expected to witness the highest CAGR, with the growth in this market centered at Japan, China, and India. The increasing number of generic drug manufacturers and rising aging populaion across are key factors driving the market in Asia. However, availability of alternative treatments is going to restrain this market.
Key players operating in the Parkinson’s disease treatment market include Teva (Israel), Novartis AG (Switzerland), GSK (UK), AbbVie (US), Merck (US), Boehringer Ingelheim (Germany), Impax Laboratories (US), Lundbeck (Denmark), UCB (Belgium), Valeant Pharmaceuticals (Canada), Acadia (US), Sun Pharma (India), Wockhardt (India), Dr. Reddy’s (India), Intas (India), US WorldMeds (US), Zydus Cadila (India), Cipla (India), Strides (India), 1 A Pharma (India), and Upsher-Smith (US).
Parkinson's Disease Treatment
US EVERY YEAR FOR THEIR
HOME ❯ TOP MARKET REPORTS ❯ PARKINSON'S DISEASE TREATMENT MARKET
Parkinson's Disease Treatment Market by Drug Class
(Carbidopa/Levodopa, Dopamine Receptor Agonists, MAO-Inhibitors),
Distribution Channel (Hospital, Online, Retail Pharmacies), Patient
Care Setting (Hospitals, Clinics) - Global Forecast to 2022
[113 Pages Report] The Parkinson’s disease treatment market was valued at USD 3.99 billion in
2016 and expected to grow at a CAGR of 6.1% from 2017 to 2022 to reach USD 5.69 billion in 2022.
The carbidopa/levodopa drug class is projected to register highest CAGR during forecast period. The
major driving factors for this market include ageing population and government funding for
research, growing healthcare awareness. The base year considered for the study is 2016, and the
forecast has been provided for the period between 2018 and 2023.
Growth in ageing population and the associated increase in the prevalence of parkinson’s
Government funding for research
Availability of alternative treatments
Patent expiry of branded drugs
The objectives of this study are as follows:
To define, describe, and forecast the global Parkinson’s disease therapeutic drugs market by
drug class, distribution channel, treatment facility, and region
To provide detailed information regarding the major factors influencing market growth (drivers,
restraints, and opportunities)
To strategically analyze micromarkets with respect to individual growth trends, prospects, and
contributions to the overall market
To analyze the opportunities in the market for stakeholders and provide details of the
competitive landscape for market leaders
To forecast the size of the market segments with respect to four main regions, namely, North
America, Europe, Asia, and the Rest of the World (RoW)